Development of Ga-67 Maltolate Complex as an Imaging Agent

Due to the antitumor activity of gallium mal complex, as well as recent findings on new targeted biomolecules in malignant cells through this complex, the development of radiolabeled gallium complex for future imaging studies was targeted. ga-67 labeled 3-hydroxy-2-methyl-4h-pyran-4-onate (ga-67 mal) was prepared using freshly prepared ga-67 chloride and 3-hydroxy-2-methyl-4h-pyran-4-onate in a sodium salt form in 25 min at 40° c. the stability of the complex was checked in final formulation and human serum for 24 h followed by the administration in swiss mice for biodistribution studies. the complex was prepared in high radiochemical purity (> 97% itlc, > 98% hplc) and specific activity of 13-14 gbq/mmol and was stable in the presence of serum for 48 h. the partition coefficient was calculated for the compound (log p = 0.40). a detailed comparative pharmacokinetic study was performed for ga-67 cation and ga-67-mal. the complex is more rapidly washed out from the circulation through kidneys and liver compared to ga-67 cation and can be an interesting tumor imaging agent due to the fact that the cold compound is undergoing clinical trials as a safe and potential therapeutic agent for cancer